Podbit · The Twenty Minute VC (20VC): Venture Capital | Startup Funding | The Pitch
Fred Turner sold a hard-won CLIA lab license for $150,000 to pay creditors when his sepsis company died. Five months later, he had to pay $27 million to acquire an equivalent license when COVID hit. The same asset, priced by the pandemic.
Where this was said
At 15:25 · chapter starts 7:00
Fred's first company, TL Biolabs, began after he won the UK National Science & Engineering Competition and was approached by a farmer to test his cows' genetics for muscle yield and milk production. He applied to Y Combinator six days before the deadline — on the advice of a YC alum he met at an AgTech conference in San Francisco — and joined the Summer 2016 batch, raising a $1.65 million seed from Andreessen Horowitz's bio fund. But a Series A proved impossible once investors ran the TAM: 100 million US cows at $15-20 per test caps the market at $1.5 billion. The team pivoted the core DNA-testing technology first to high-throughput STD testing, identifying antibiotic resistance in sexually transmitted infections as a compelling and growing problem. Fred notes STD rates are continuing to rise despite people having less sex — a detail that generates genuine surprise from Harry. A second pivot followed into sepsis diagnostics, a market Fred describes with striking precision: bacteria in the bloodstream trigger the immune system to destroy the body's own organs, and every untreated hour raises mortality by 12% [1] — Fred Turner "Sepsis: 12% mortality increase per hour untreated: Every hour sepsis goes untreated, a patient's mortality risk increases by approximately …" 14:14 . The company renamed Shield, raised a Series A, built working prototypes, and pursued FDA approval — before a strategic acquirer's CEO killed a signed term sheet after three weeks of document work. With three weeks of cash left, Fred sold the company's hard-won CLIA lab license for $150,000 and began winding down. Five months later, that same license would have been worth $27 million [2] — Fred Turner "I sold that license to a company in San Diego for $150,000 to pay some of the creditors. And then 5 months later, acquired a company in Sou…" 15:45 .
Fred Turner's path from sequencing dairy cows in northern England to building a $5B COVID testing company ran through Y Combinator, a failed sepsis diagnostics startup, and a chance tweet from a longevity researcher. Every company failure was a prerequisite for the next pivot.
Every hour sepsis goes untreated, a patient's mortality risk increases by approximately 12%, making rapid diagnosis critical.
Fred Turner sold a critical CLIA lab license for $150,000 during wind-down, then was forced to acquire an equivalent license 5 months later for $27 million when COVID hit.
PropGPT launched with 20 downloads a day and strong influencer marketing but hit a ceiling at $1,000–$2,000 MRR. High download numbers masked a critical flaw: almost nobody stuck around after the free trial ended.
Eyal and Yali made a bold bet: stop all marketing, go back into the cave, and rebuild PropGPT from scratch. Four months of pure engineering and design work with zero revenue growth — and it paid off massively.
After rebuilding, PropGPT relaunched at $1,700 MRR. Within 2.5 months, it peaked at $40K MRR and 2,000 downloads in a single day. The product hadn't changed its audience — it had changed how well it served them.
Users didn't want a sports betting analytics tool — they wanted to be told the answer. Eyal realized their app was making users do the work when they just wanted the result, and that single insight drove the entire rebuild.
Step 1: know exactly who you're building for. Step 2: worship your data. Step 3: obsess over in-app analytics to find drop-off points. Step 4: scale with influencer marketing only after the product converts. In that order.
A 45% download-to-trial rate sounds great — until you see 13% trial-to-paid. That gap isn't a marketing problem. It's a product problem. Eyal breaks down how to read these signals before they kill your business.
Their 70th influencer video hit 600,000 views and single-handedly pushed PropGPT's ARR from $8,000 to $38,000 in three days. Influencer marketing has a lottery-like upside — but only if the product can hold the users it acquires.
Most founders struggle with distribution. Eyal and Yali had it nailed from day one — and still failed. Their story proves the rarer, less-discussed truth: a great go-to-market strategy is worthless if the product can't retain users.
Get a co-founder who has your back. Be scientifically honest about whether your idea has real demand. Once you convince yourself, it becomes an order of magnitude easier to convince investors and team members to join you.
We use essential and analytics cookies to run Vuci. To understand how the site is used: Privacy Policy.
Install Vuci on your phone
Add it to your home screen for a faster, app-like experience.
Install Vuci on your phone
Tap the Share button, then “Add to Home Screen”.
A new version is available
Reload to get the latest Vuci.